Safety pharmacology assessment of biopharmaceuticals

Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays, Second Edition

Volumn , Issue , 2013, Pages 555-560

  Amouzadeh, Hamid R ^a   Vargas, Hugo M ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891276698     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-25240-2_18     Document Type: Chapter

References (34)

1. Amouzadeh H, Vargas HM (2012) A review of convulsion and seizure incidence: small versus large molecule experience. J Pharmacol Toxicol Methods (in preparation).
2. Bussiere JL, Martin P, Horner M, Couch J, Flaherty M, Andrews L, Beyer J, Horvath C (2009) Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int J Toxicol 28:230-253
3. Chapman K, Pullen N, Graham M, Ragan I (2007) Preclinical safety testing of biological: the significance of species relevance. Nature Drug Discovery 6:120-126
4. Chui RW, Fosdick A, Conner R, Jiang J, Bruenner BA, Vargas HM (2009) Assessment of two external telemetry systems (PhysioJacket™ and JETtm) in beagle dogs with telemetry implants. J Pharmacol Toxicol Methods 60:58-68
5. Chui RW, Derakhchan K, Vargas HM (2011) Long-term assessment of non-human primate ECG using jacketed external telemetry (JET): evaluation of heart rate and QTc interval variation over 6 months of observation. J Pharmacol Toxicol Methods 64:e45
6. Crommelin DJA, Storm G, Verrijk R, de Leede L, Jiskoot W, Hennick WE (2003) Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharmaceutics 266:3-16
7. Derakhchan K, Chui RW, Vargas HM (2011) Evaluation of cardiac conduction disturbances using jacketed external telemetry (JET) in conscious non-human primates. J Pharmacol Toxicol Methods 64:e46
8. Foster CD, Hunter TC, Gibbs PH, Leffel EK (2008) Whole-body plethysmography in African green monkeys (Chlorocebus aethiops) with and without jackets. J Am Assoc Lab Anim Sci 47:52-55
9. Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1:55-68
10. Giezen TJ, Mantel-Teeuwisse AK, Straus SJJM, Schellekens H, Leufkens HGM, Egherts ACG (2008) Safety-related regulatory actions for biologicals approved in the United States and the European Union. J Am Med Assoc 300:1887-1896
11. Gosse ME, DiMasi JA, Nelson TF (1996) Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980-1994. Clin Pharmacol Ther 60:608-618
12. Green MD (1997) Problems associated with the absence of activity in standard models of safety pharmacology used to assess biologic products. International J Toxicol 16:33-40
13. Guengerich FP (2011) Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet 26:3-14
14. Guth BD, Bass AS, Briscoe R, Chivers S, Markert M, Siegl PKS, Valentin JP (2009) Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicology studies. J Pharmacol Toxicol Methods 60:107-116
15. ICH S6(R1) (2011) Preclinical Safety Evaluation of Biotechnology-Derived Biopharmaceuticals. Retrieved February 2012 from http://www.ich.org.
16. ICH S7A (2000), Safety Pharmacology Studies for Human Biopharmaceuticals. Retrieved February 2012 from http://www.ich.org.
17. ICH S7B (2005) Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT interval prolongation) by Human Biopharmaceuticals. Retrieved February 2012 from http://www.ich.org.
18. Iizuka H, Sasaki K, Odagiri N, Obo M, Imaizumi M, Atai H (2010) Measurement of respiratory function using whole-body plethysmography in unanesthetized and unrestrained non-human primates. J Toxicol Sci 35:863-870
19. Kaiser RA, Erwin R, Tichenor SD, Regalia DE, Meyer DJ (2010) Integration of cardiovascular safety pharmacology endpoints into general toxicology studies. J Pharmacol Toxicol Methods 62:e30
20. Korte S, Fuchs A, Weinbauer GF, Moscardo E, Giarola A (2007) Modified Irwin test as diagnostic tool to monitor neurobehavioral changes in monkeys. J Pharmacol Toxicol Methods 56:e47
21. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE (2005) Recommendations for blood pressure measurement in humans and animals. Hypertension 45:299-310
22. Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nature Reviews 7:21-39
23. Lowe JA, Jones P (2007) Biopharmaceuticals and the future of the pharmaceutical industry. Cur Opin Drug Disc Develop 10:513-514
24. McMahon C, Mitchell AZ, Klein JL, Jenkins AC, Sarazan RD (2010) Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys. J Pharmacol Toxicol Methods 62:127-135
25. Nakazawa T, Kurokawa KK, Wakata A, Hisada S, Inoue T, Sagami F, Heidel SM, Kawakami K, Shinoda K, Onodera H, Kumagai Y, Ohno Y, Kawamura N, Yamazaki T, Inoue T (2008) Safety assessment of biopharmaceuticals: Japanese perspective on ICH S6 guideline maintenance. J Toxicol Sci 33:277-282
26. Pardridge WM (2005) The blood brain barrier: bottleneck in brain drug development. Neurorx 2:3-14
27. Qu Y, Fang M, Gao B, Chui RW, Vargas HM (2011) BeKm-1, a peptide inhibitor of hERG potassium currents, prolongs QTc interval in isolated rabbit hearts. J Pharmacol Exp Ther 337:2-8
28. Santostefano MJ, Kirchner J, Vissinga C, Fort M, Lear S, Pan W-J, Prince PJ, Hensley KM, Tran D, Rock D, Vargas HM, Narayanan P, Jawando R, Rees W, Reindel JF, Reynhardt K, Everds N (2012) Off-target platelet activation in macaques unique to a therapeutic monoclonal antibody. Toxicol Sci (in press)
29. Schmelting B, Neihoff M, Egner B, Korte SH, Weinbauer GF (2009) High-definition oscillometry: a novel technique for non-invasive blood pressure monitoring in the cynomolgus monkey. J Med Primatol. 38(5):293-301
30. Schwieterman WD (2006) Regulating biopharmaceuticals under CDER versus CBER: an insider’s perspective. Drug Disc Today 11:945-951
31. Tabrizi MA, Tseng CML, Roskos LK (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discovery Today 11:81-88
32. Vargas HM, Bass AS, Breidenbach A, Feldman HS, Gintant GA, Harmer A, Heath B, Hoffmann P, Lagrutta A, Leishmann D, McMahon N, Mittelstadt SW, Polonchuk L, Pugsley MK, Salata JJ, Valentin JP (2008) Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 58:72-76
33. Vargas HM, Derakhchan K, Chui RW, Stevens DW (2010) Evaluation of D, L-sotalol using jacketed external telemetry (JET) in conscious non-human primates over 4 weeks of evaluation. J Pharmacol Toxicol Methods 64:e24-e25
34. Wernick MB, Hopfner RM, Francey T, Howard J (2012) Comparison of arterial blood pressure measurements and hypertension scores obtained by use of three indirect measurement devices in hospitalized dogs. J Am Vet Med Assoc 240:962-968